vs
Side-by-side financial comparison of BELDEN INC. (BDC) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
BELDEN INC. is the larger business by last-quarter revenue ($696.4M vs $622.0M, roughly 1.1× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 7.3%, a 27.1% gap on every dollar of revenue. On growth, BELDEN INC. posted the faster year-over-year revenue change (11.4% vs 4.8%). Over the past eight quarters, BELDEN INC.'s revenue compounded faster (7.3% CAGR vs 4.6%).
Belden Inc. is an American, multinational, publicly traded company specializing in the design, manufacture, and distribution of end-to-end networking, security and connectivity products. The company serves the Industrial Automation Solutions, Smart Buildings and Broadband & 5G markets.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
BDC vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $696.4M | $622.0M |
| Net Profit | $51.0M | $214.2M |
| Gross Margin | 37.1% | — |
| Operating Margin | 11.2% | 62.4% |
| Net Margin | 7.3% | 34.4% |
| Revenue YoY | 11.4% | 4.8% |
| Net Profit YoY | -1.8% | 2.9% |
| EPS (diluted) | $1.30 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $696.4M | — | ||
| Q4 25 | $720.1M | $622.0M | ||
| Q3 25 | $698.2M | $609.3M | ||
| Q2 25 | $672.0M | $578.7M | ||
| Q1 25 | $624.9M | $568.2M | ||
| Q4 24 | $666.0M | $593.6M | ||
| Q3 24 | $654.9M | $564.7M | ||
| Q2 24 | $604.3M | $537.3M |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $67.9M | $214.2M | ||
| Q3 25 | $56.7M | $288.2M | ||
| Q2 25 | $61.0M | $30.2M | ||
| Q1 25 | $51.9M | $238.3M | ||
| Q4 24 | $58.4M | $208.2M | ||
| Q3 24 | $53.7M | $544.0M | ||
| Q2 24 | $49.0M | $102.0M |
| Q1 26 | 37.1% | — | ||
| Q4 25 | 36.6% | — | ||
| Q3 25 | 37.7% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 39.3% | — | ||
| Q4 24 | 37.5% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.5% | — |
| Q1 26 | 11.2% | — | ||
| Q4 25 | 12.2% | 62.4% | ||
| Q3 25 | 10.9% | 70.1% | ||
| Q2 25 | 11.8% | 36.3% | ||
| Q1 25 | 11.6% | 94.0% | ||
| Q4 24 | 10.4% | 60.9% | ||
| Q3 24 | 11.5% | — | ||
| Q2 24 | 11.4% | 50.2% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 9.4% | 34.4% | ||
| Q3 25 | 8.1% | 47.3% | ||
| Q2 25 | 9.1% | 5.2% | ||
| Q1 25 | 8.3% | 41.9% | ||
| Q4 24 | 8.8% | 35.1% | ||
| Q3 24 | 8.2% | 96.3% | ||
| Q2 24 | 8.1% | 19.0% |
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.70 | $0.49 | ||
| Q3 25 | $1.41 | $0.67 | ||
| Q2 25 | $1.53 | $0.07 | ||
| Q1 25 | $1.27 | $0.55 | ||
| Q4 24 | $1.41 | $0.46 | ||
| Q3 24 | $1.30 | $1.21 | ||
| Q2 24 | $1.19 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $272.2M | $618.7M |
| Total DebtLower is stronger | $1.3B | $9.0B |
| Stockholders' EquityBook value | $1.3B | $9.7B |
| Total Assets | — | $19.6B |
| Debt / EquityLower = less leverage | 0.98× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $272.2M | — | ||
| Q4 25 | $389.9M | $618.7M | ||
| Q3 25 | $314.3M | $938.9M | ||
| Q2 25 | $301.5M | $631.9M | ||
| Q1 25 | $259.0M | $1.1B | ||
| Q4 24 | $370.3M | $929.0M | ||
| Q3 24 | $323.0M | $950.1M | ||
| Q2 24 | $564.8M | $1.8B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.2B | $9.8B | ||
| Q4 24 | $1.3B | $10.3B | ||
| Q3 24 | $1.2B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B |
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $19.6B | ||
| Q3 25 | $3.4B | $19.3B | ||
| Q2 25 | $3.4B | $18.3B | ||
| Q1 25 | $3.3B | $17.6B | ||
| Q4 24 | $3.3B | $18.2B | ||
| Q3 24 | $3.3B | $18.0B | ||
| Q2 24 | $3.5B | $17.7B |
| Q1 26 | 0.98× | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | $-63.1M | — |
| FCF MarginFCF / Revenue | -9.1% | — |
| Capex IntensityCapex / Revenue | 6.4% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $180.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $160.4M | $827.1M | ||
| Q3 25 | $105.0M | $702.6M | ||
| Q2 25 | $82.0M | $364.0M | ||
| Q1 25 | $7.4M | $596.1M | ||
| Q4 24 | $174.7M | $742.5M | ||
| Q3 24 | $91.7M | $703.6M | ||
| Q2 24 | $83.0M | $658.2M |
| Q1 26 | $-63.1M | — | ||
| Q4 25 | $121.3M | — | ||
| Q3 25 | $65.3M | — | ||
| Q2 25 | $56.9M | — | ||
| Q1 25 | $-24.8M | — | ||
| Q4 24 | $116.4M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $61.0M | — |
| Q1 26 | -9.1% | — | ||
| Q4 25 | 16.8% | — | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 8.5% | — | ||
| Q1 25 | -4.0% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 10.1% | — |
| Q1 26 | 6.4% | — | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 3.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.36× | 3.86× | ||
| Q3 25 | 1.85× | 2.44× | ||
| Q2 25 | 1.34× | 12.06× | ||
| Q1 25 | 0.14× | 2.50× | ||
| Q4 24 | 2.99× | 3.57× | ||
| Q3 24 | 1.71× | 1.29× | ||
| Q2 24 | 1.69× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDC
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
